Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

1
Strategies for the Management of EGFR TKI
Resistance in Advanced NSCLC
2
(No Transcript)
3
Program Goals
4
EGFR TKI Resistance
5
ATP and Erlotinib Binding to EGFR
6
Resistance to TKIs in Other Systems
7
When is Progression Significant Enough to Change
Therapy?
8
The Need to Rebiopsy
9
Radiation With Concurrent Gefitinib or Erlotinib
10
Systemic Therapy
11
Rapid Progression With Discontinuation of EGFR
TKI in Acquired Resistance
12
Leptomeningeal Disease
13
Afatinib vs Placebo (LUX-Lung 1) Phase 2b/3 Study
14
Afatinib Cetuximab Responses at MTD
15
Clinical Trials in NSCLC With Acquired Resistance
16
Abbreviations
17
Abbreviations (cont)
18
Abbreviations (cont)
19
References
20
References (cont)
21
References (cont)
22
References (cont)
23
References (cont)
24
References (cont)
25
References (cont)